By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Esperion Therapeutics, Inc. 

3621 S. State Street
695 KMS Place
Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-332-0506 Fax: 734-332-0516

Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, "HDL-C", also known as the "good" cholesterol.

The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company's product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases.

Esperion was founded in 1998 by, among others, members of the Warner-Lambert/Parke-Davis (now Pfizer) team that discovered and developed atorvastatin, the highly successful multibillion-dollar drug. Since that time, an additional group of exceptional scientists and specialists has joined the Company. Many of these individuals have been instrumental in the discovery, development and commercialization of several of the pharmaceutical industry's most successful therapies. It is this combined team that makes Esperion a leading enterprise in HDL drug discovery and research.

Key Management:

  • Roger Newton, Ph.D.
    President and CEO
  • Timothy Mayleben
    Chief Operating Officer and CFO

    Last Updated: 01-18-05

    Key Statistics

    Ownership: Public

    Web Site: Esperion
    Symbol: ESPR

  • Industry

    Company News
    Esperion (ESPR) To Present At November Healthcare Conferences 11/6/2015 11:13:21 AM
    Esperion (ESPR) Provides ETC-1002 Development Program Update; Reports Third Quarter 2015 Financial Results 11/6/2015 9:36:40 AM
    Esperion (ESPR) Announces Two Oral Presentations For ETC-1002 At American Heart Association Scientific Sessions 2015 11/5/2015 10:35:29 AM
    Esperion (ESPR) Stock Plummets as Updates on ETC-1002 Prove Not Enough for Investors 9/29/2015 8:25:34 AM
    Amgen (AMGN)'s Acquisition Of Dezima Pharma And CETP Drug Like Pfizer (PFE)'s '03 Buy Of Esperion (ESPR). Will History Repeat? 9/17/2015 7:00:10 AM
    Esperion (ESPR) Provides Update On The ETC-1002 Development Program Following End-Of-Phase II Meeting With FDA 8/18/2015 7:20:10 AM
    Esperion (ESPR) Rockets as Lead Drug ETC-1002 Will Not Require Heart Trial for FDA Approval 8/18/2015 6:35:11 AM
    Esperion Therapeutics (ESPR) Provides ETC-1002 Development Program Update; Reports Second Quarter 2015 Financial Results 8/7/2015 2:01:14 PM
    Esperion Therapeutics (ESPR) To Provide Second Quarter Program Updates And Financial Results 7/29/2015 9:26:16 AM
    Esperion Therapeutics (ESPR) Announces Positive Top-Line Phase 2 Results For ETC-1002 In Patients With Hypercholesterolemia And Hypertension 7/28/2015 9:39:48 AM